Zhou Yu, Brigstock David, Besner Gail E
Department of Pediatric Surgery, The Ohio State University College of Medicine, Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.
Microvasc Res. 2009 Jun;78(1):78-85. doi: 10.1016/j.mvr.2009.04.006. Epub 2009 Apr 21.
We have previously shown that heparin-binding EGF-like growth factor (HB-EGF) protects the intestines from multiple forms of injury via direct cytoprotective effects on the intestinal mucosa. In this study, we examined the effects of HB-EGF on the hemodynamics of intestinal arterioles, the major resistance vessels that regulate blood flow to the intestines, as an additional mechanism of HB-EGF-mediated intestinal protection.
The hemodynamic effects of HB-EGF in rodent terminal mesenteric arterioles and human submucosal arterioles were examined ex vivo using a video dimension analyzer. Cultured human intestinal microvascular endothelial cells (HIMEC) were used to elucidate the mechanisms of HB-EGF-induced vasodilation.
HB-EGF significantly increased vessel diameter under conditions of increasing intraluminal pressure and increased flow rate. These HB-EGF-mediated vasodilatory effects were observed in terminal mesenteric arterioles from adult rats and 3 day old rat pups. These effects were confirmed in submucosal arterioles from human intestine. Furthermore, HB-EGF significantly reduced endothelin-1-induced mesenteric arteriolar vasoconstriction. The vasodilatory effects of HB-EGF were blocked by ET(B) receptor antagonism in adult rat arterioles, and also by nitric oxide synthase inhibition in rat pup and human infant arterioles. In HIMEC, HB-EGF significantly increased endothelin B (ET(B)) receptor protein expression and provoked intracellular calcium mobilization.
HB-EGF is a potent vasodilator of the intestinal microvasculature, further supporting its use in diseases manifested by decreased intestinal blood flow, including necrotizing enterocolitis.
我们之前已经表明,肝素结合表皮生长因子(HB-EGF)通过对肠黏膜的直接细胞保护作用,保护肠道免受多种形式的损伤。在本研究中,我们研究了HB-EGF对肠小动脉血流动力学的影响,肠小动脉是调节肠道血流的主要阻力血管,这是HB-EGF介导的肠道保护的另一种机制。
使用视频尺寸分析仪在体外研究HB-EGF对啮齿动物终末肠系膜小动脉和人黏膜下小动脉血流动力学的影响。培养的人肠微血管内皮细胞(HIMEC)用于阐明HB-EGF诱导血管舒张的机制。
在管腔内压力增加和流速增加的情况下,HB-EGF显著增加血管直径。在成年大鼠和3日龄大鼠幼崽的终末肠系膜小动脉中观察到这些HB-EGF介导的血管舒张作用。在人肠黏膜下小动脉中也证实了这些作用。此外,HB-EGF显著降低内皮素-1诱导的肠系膜小动脉血管收缩。在成年大鼠小动脉中,ET(B)受体拮抗剂可阻断HB-EGF的血管舒张作用,在大鼠幼崽和人类婴儿小动脉中,一氧化氮合酶抑制剂也可阻断该作用。在HIMEC中,HB-EGF显著增加内皮素B(ET(B))受体蛋白表达并引发细胞内钙动员。
HB-EGF是肠微血管的一种强效血管舒张剂,进一步支持其在以肠血流量减少为特征的疾病中的应用,包括坏死性小肠结肠炎。